[Fibrinolytic and hypoglycemic effects of the Pro-Gly-Pro-Leu peptide during development of insulin-dependent diabetes in rats]

Izv Akad Nauk Ser Biol. 2010 May-Jun:(3):375-9.
[Article in Russian]

Abstract

Repeated (over 7 days) intranasal introduction of the Pro-Gly-Pro-Leu peptide into animals at a dose of 1 mg/kg before injection of the diabetogenic metabolite alloxan provided effective protection of an organism against development of insulin-dependent diabetes mellitus and prevented development of hypercoagulating alterations in the system of hemostasis. An increasing in the anticoagulating and fibrinolytic activities in rat blood plasma was detected. The peptide under study also showed antidiabetogenic action: repeated intranasal introduction of the Pro-Gly-Pro-Leu peptide into animals for 7 days inhibited development of diabetes symptoms in rats pretreated with alloxan.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Alloxan
  • Animals
  • Blood Glucose / analysis
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / prevention & control*
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / chemically induced
  • Diabetes Mellitus, Type 1 / prevention & control*
  • Fibrinolysis / drug effects
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / therapeutic use*
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use*
  • Male
  • Oligopeptides / administration & dosage
  • Oligopeptides / therapeutic use*
  • Rats
  • Time Factors

Substances

  • Blood Glucose
  • Fibrinolytic Agents
  • Hypoglycemic Agents
  • Oligopeptides
  • prolyl-glycyl-prolyl-leucine
  • Alloxan